ClinicalTrials.gg
CompletedNCT03816761Updated Jun 11, 2020Results posted

Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes

A Phase 2 interventional study of Fast-acting insulin aspart and iLet™ in Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-11.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Insulin Aspart · Diabetes Mellitus, Type 1.

Enrollment
73rd of 87
24 · median 50
Started
2019
with 6 others
Phase 2
Only one
of the 87
Registered
76th of 87
by date
Lead sponsor
55 of 87
Novo Nordisk A/S

Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, this one is the 73rd largest by enrollment, is one of 7 that started in 2019, is the only one in phase 2, and was the 76th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Insulin Aspart

Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

The iLet™ is a new insulin pump that is programmed to work with a Continuous Glucose Monitoring (CGM) device. This is to give participants insulin automatically. The CGM device is already available for sale. The iLet™ is not yet approved for use. Fast-acting insulin aspart is a type of insulin that doctors can already prescribe for use with insulin pens, but not for use in an insulin pump. This study is to test how safe fast acting insulin aspart is when used with different insulin delivery settings in the iLet™ in people with type 1 diabetes. Participants will get fast-acting insulin aspart as participants' insulin and use the iLet™ as participants' insulin pump with a CGM device. Participants' iLet™ will be set to 2 different insulin delivery settings for 7 days on each setting. The setting participants get first is decided by chance. The study will last for about 5 to 9 weeks. Participants will have 4 visits and 1 phone contact with the study or staff.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
  • Male or female, age more than or equal to 18 years and less than or equal to 75 years at the time of signing informed consent
  • Diagnosed with type 1 diabetes mellitus more than or equal to 1 year prior to the day of screening
  • Treated with continuous subcutaneous insulin infusion more than or equal to 1 year prior to the day of screening
  • Have a mean total daily dose of insulin more than or equal to 20 units
  • Familiar with continuous glucose monitoring as judged by the investigator
  • Has someone over 18 years of age who (i) lives with them, (ii) has access to where they sleep, (iii) is willing to be in the house when the subject is sleeping, and (iv) is willing to receive calls from the study staff and check the welfare of the study subject
  • (BMI) less than or equal to 35.0 kg/m\^2 at screening
  • (HbA1c) more than or equal to 6.5% (47 mmol/mol) and less than or equal to 9% (75 mmol/mol) at screening
  • Able and willing to remain in a designated place for the specified duration of the 'in-patient' periods
  • Lives within a 120-minute drive away from the central monitoring location (site)

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to trial product(s) or related products
  • Previous participation in this trial. Participation is defined as signed
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using an adequate method (adequate contraceptive measures as required by local regulation or practice)
  • Participation in any clinical trial of an approved or non-approved medicinal product within 30 days before screening
  • Any disorder, except for conditions associated with diabetes mellitus, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol
  • Anticipated initiation or change in concomitant medications known to affect weight or glucose metabolism during the trial
  • Impaired liver function, defined as (ALT) more than or equal to 2.5 times or more than 1.5 times upper normal limit at screening
  • Renal impairment measured as estimated (eGFR) value of eGFR less than 60 ml/min/1.73 m\^2
  • Any episodes of diabetic ketoacidosis within the past 90 days prior to the day of screening
  • Known hypoglycaemic unawareness as indicated by the Investigator according to Clarke's questionnaire question 8
  • Recurrent severe hypoglycaemic episodes within the last year as judged by the Investigator
  • Any of the following: myocardial infarction, stroke, hospitalization for unstable angina pectoris or within the past 180 days prior to the day of screening
  • Subjects presently classified as being in (NYHA) Class IV
  • Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
  • Inadequately treated blood pressure defined as Grade 3 hypertension or higher (systolic more than or equal to 180 mmHg or diastolic more than or equal to 110 mmHg) at screening
  • Unwilling or unable to avoid acetaminophen throughout the trial
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Fast-acting insulin aspart, default tmax setting

    Participants will receive fast-acting insulin aspart using the iLet™ with default tmax setting (t65 = 65 minutes) in two different treatment periods in a cross-over manner. There will be 3 different cohorts with 2 treatment periods in each cohort.

    Drug: Fast-acting insulin aspart · Device: iLet™

  • Experimental
    Fast-acting insulin aspart, non-default tmax setting

    Participants will receive fast-acting insulin aspart using the iLet™ with non-default tmax setting (t50 = 50 minutes, t40 = 40 minutes or t30 = 30 minutes) in two different treatment periods in a cross-over manner. There will be 3 different cohorts with 2 treatment periods in each cohort.

    Drug: Fast-acting insulin aspart · Device: iLet™

Interventions

  • In each cohort, participants will receive fast-acting insulin aspart using the iLet™ in a cross-over manner for 14 days (7days per period). Dose modification will be handled autonomously by the iLet™ based on the CGM sensor readings and the user interaction with the iLet™ e.g. meal announcements.

  • DeviceiLet™

    The bionic pancreas including pigtail adapters, used in insulin-only configuration

06

What researchers measure

Primary outcomes

  1. Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage)

    Interstitial glucose: glucose measured in interstitial fluid. Time in low interstitial glucose (defined as below 54 mg/dL \[3 mmol/L\]) from initiation of treatment (day 1) to end of treatment (day 7). Time spent in low interstitial glucose is calculated as the percentage of available interstitial glucose values below the threshold.

    Time frame: Day 1 to day 7

  2. Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage) - Median

    Interstitial glucose: glucose measured in interstitial fluid. Time in low interstitial glucose (defined as below 54 mg/dL \[3 mmol/L\]) from initiation of treatment (day 1) to end of treatment (day 7). Time spent in low interstitial glucose is calculated as the percentage of available interstitial glucose values below the threshold.

    Time frame: Day 1 to day 7

Secondary outcomes

  1. Number of Treatment Emergent Severe Hypoglycaemic Episodes

    Number of treatment emergent severe hypoglycaemic episodes from initiation of treatment (day 1) to end of treatment (day 7). Treatment emergent is defined as an episode that has onset in the period from initiation of treatment to end of treatment. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. Plasma glucose (PG) concentrations may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by a low PG concentration.

    Time frame: Day 1 to day 7

  2. Number of Self-manageable (Able to Self-treat) Treatment Emergent Hypoglycaemic Episodes That Require Oral Carbohydrate Intervention Per Day

    Mean number of self-manageable (able to self-treat) treatment emergent hypoglycaemic episodes that require oral carbohydrate intervention per day. Self-manageable (able to self-treat) hypoglycaemic episodes that require oral carbohydrate intervention per day is calculated as the sum of all hypoglycaemic episodes where the subject is able to self-treat and that require oral carbohydrate intervention divided by the actual duration of the treatment period in days. Treatment emergent is defined as an episode that has onset in the period from initiation of treatment to end of treatment.

    Time frame: Day 1 to day 7

  3. Number of Treatment Emergent Overall Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition

    ADA classification of hypoglycaemia: 1. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. 2. Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL). 3. Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL). 4. Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a measured PG concentration \> 3.9 mmol/L (70 mg/dL) but approaching that level. 5. Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia are not accompanied by a PG determination but that was presumably caused by a PG concentration ≤ 3.9 mmol/L (70 mg/dL).

    Time frame: Day 1 to day 7

  4. Number of Treatment Emergent Overall Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification

    Overall hypoglycaemia count according to Novo Nordisk classification. Novo Nordisk classification of hypoglycaemia: 1. Severe hypoglycaemia according to the ADA classification. 2. Symptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3. Asymptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) without symptoms consistent with hypoglycaemia. 4. BG confirmed hypoglycaemia: The union of 2. and 3. 5. Severe or BG confirmed symptomatic hypoglycaemia: The union of 1. and 2. 6. Severe or BG confirmed hypoglycaemia: The union of 1., 2. and 3.

    Time frame: Day 1 to day 7

  5. Number of Treatment Emergent Daytime Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition

    ADA classification of hypoglycaemia: 1. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. 2. Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL). 3. Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL). 4. Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a measured PG concentration \> 3.9 mmol/L (70 mg/dL) but approaching that level. 5. Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia are not accompanied by a PG determination but that was presumably caused by a PG concentration ≤ 3.9 mmol/L (70 mg/dL).

    Time frame: Day 1 to day 7 (in both the treatment periods)

  6. Number of Treatment Emergent Daytime Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification

    Number of daytime hypoglycaemic episodes according to Novo Nordisk classification. Novo Nordisk classification of hypoglycaemia: 1. Severe hypoglycaemia according to the ADA classification. 2. Symptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3. Asymptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) without symptoms consistent with hypoglycaemia. 4. BG confirmed hypoglycaemia: The union of 2. and 3. 5. Severe or BG confirmed symptomatic hypoglycaemia: The union of 1. and 2. 6. Severe or BG confirmed hypoglycaemia: The union of 1., 2. and 3.

    Time frame: Day 1 to day 7

  7. Number of Treatment Emergent Nocturnal Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition

    ADA classification of hypoglycaemia: 1. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. 2. Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL). 3. Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL). 4. Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a measured PG concentration \> 3.9 mmol/L (70 mg/dL) but approaching that level. 5. Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia are not accompanied by a PG determination but that was presumably caused by a PG concentration ≤ 3.9 mmol/L (70 mg/dL).

    Time frame: Day 1 to day 7

  8. Number of Treatment Emergent Nocturnal Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification

    Number of nocturnal (from time 00:01-05:59 both inclusive) hypoglycaemic episodes according to Novo Nordisk classification. Novo Nordisk classification of hypoglycaemia: 1. Severe hypoglycaemia according to the ADA classification. 2. Symptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3. Asymptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) without symptoms consistent with hypoglycaemia. 4. BG confirmed hypoglycaemia: The union of 2. and 3. 5. Severe or BG confirmed symptomatic hypoglycaemia: The union of 1. and 2. 6. Severe or BG confirmed hypoglycaemia: The union of 1., 2. and 3.

    Time frame: Day 1 to day 7 (in both the treatment periods)

  9. Time in Interstitial Glucose Range Was Defined as 70-180 mg/dL (3.9-10 mmol/L) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentages)

    Time in interstitial glucose range defined as 70-180 mg/dL (3.9-10 mmol/L) from initiation of treatment (day 1) to end of treatment (day 7). Time spent in interstitial glucose range is calculated as the percentage of available interstitial glucose values above or equal to the low threshold and below or equal to the high threshold.

    Time frame: Day 1 to day 7

  10. Mean Interstitial-glucose Level

    Mean interstitial glucose level is calculated as the average of the available interstitial glucose values.

    Time frame: Day 1 to day 7

  11. Number of Treatment Emergent Adverse Events

    Number of treatment emergent adverse events from initiation of treatment (day 1) to end of treatment (day 7). Treatment emergent is defined as an event that has onset in the period from initiation of treatment to end of treatment.

    Time frame: Day 1 to day 7

  12. Number of Treatment Emergent Infusion Site Reactions

    Number of treatment-emergent infusion site reactions from initiation of treatment (day 1) to end of treatment (day 7). Treatment emergent is defined as an event that has onset in the period from initiation of treatment to end of treatment.

    Time frame: Day 1 to day 7

  13. Total Insulin Dose Per Day

    Total insulin dose (U/kg) per day from initiation of treatment (day 1) to end of treatment (day 7). Total daily insulin dose is calculated as the sum of all insulin doses delivered by the iLet™ divided by the actual duration of the treatment period in days.

    Time frame: Day 1 to day 7

07

Results

Posted Jun 11, 2020

Participant flow

The trial was conducted at one site in the United States.

First Treatment Period (7 Days)
Participant flow — First Treatment Period (7 Days)
MilestoneCohort 1: t65 First, Then t50Cohort 1: t50 First, Then t65Cohort 2: t65 First, Then t40Cohort 2: t40 First, Then t65Cohort 3: t65 First, Then t30Cohort 3: t30 First, Then t65
Started444444
Completed444443
Not completed000001
Withdrew: Withdrawal by subject000001
Second Treatment Period (7 Days)
Participant flow — Second Treatment Period (7 Days)
MilestoneCohort 1: t65 First, Then t50Cohort 1: t50 First, Then t65Cohort 2: t65 First, Then t40Cohort 2: t40 First, Then t65Cohort 3: t65 First, Then t30Cohort 3: t30 First, Then t65
Started444443
Completed444343
Not completed000100
Withdrew: Unclassified000100

Outcome measures

PrimaryTime in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage)

Interstitial glucose: glucose measured in interstitial fluid. Time in low interstitial glucose (defined as below 54 mg/dL \[3 mmol/L\]) from initiation of treatment (day 1) to end of treatment (day 7). Time spent in low interstitial glucose is calculated as the percentage of available interstitial glucose values below the threshold.

Time frame:
Day 1 to day 7
Reported as:
Mean · Percentage
Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage)
Percentaget50 Faster Aspart Cohort 1t65 Faster Aspart Cohort 1t40 Faster Aspart Cohort 2t65 Faster Aspart Cohort 2t30 Faster Aspart Cohort 3t65 Faster Aspart Cohort 3
Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage)0.98 ± 0.720.89 ± 1.160.69 ± 0.500.50 ± 0.790.61 ± 0.560.37 ± 0.41
PrimaryTime in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage) - Median

Interstitial glucose: glucose measured in interstitial fluid. Time in low interstitial glucose (defined as below 54 mg/dL \[3 mmol/L\]) from initiation of treatment (day 1) to end of treatment (day 7). Time spent in low interstitial glucose is calculated as the percentage of available interstitial glucose values below the threshold.

Time frame:
Day 1 to day 7
Reported as:
Median · Percentage
Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage) - Median
Percentaget50 Faster Aspart Cohort 1t65 Faster Aspart Cohort 1t40 Faster Aspart Cohort 2t65 Faster Aspart Cohort 2t30 Faster Aspart Cohort 3t65 Faster Aspart Cohort 3
Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage) - Median0.93 (0.2 to 2.2)0.42 (0.1 to 3.6)0.75 (0.0 to 1.4)0.20 (0.0 to 2.3)0.58 (0.0 to 1.4)0.29 (0.1 to 1.3)
SecondaryNumber of Treatment Emergent Severe Hypoglycaemic Episodes

Number of treatment emergent severe hypoglycaemic episodes from initiation of treatment (day 1) to end of treatment (day 7). Treatment emergent is defined as an episode that has onset in the period from initiation of treatment to end of treatment. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. Plasma glucose (PG) concentrations may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by a low PG concentration.

Time frame:
Day 1 to day 7
Reported as:
Number · Episodes
Number of Treatment Emergent Severe Hypoglycaemic Episodes
Episodest50 Faster Aspart Cohort 2t65 Faster Aspart Cohort 1t40 Faster Aspart Cohort 2t65 Faster Aspart Cohort 2t30 Faster Aspart Cohort 3t65 Faster Aspart Cohort 3
Number of Treatment Emergent Severe Hypoglycaemic Episodes000000
SecondaryNumber of Self-manageable (Able to Self-treat) Treatment Emergent Hypoglycaemic Episodes That Require Oral Carbohydrate Intervention Per Day

Mean number of self-manageable (able to self-treat) treatment emergent hypoglycaemic episodes that require oral carbohydrate intervention per day. Self-manageable (able to self-treat) hypoglycaemic episodes that require oral carbohydrate intervention per day is calculated as the sum of all hypoglycaemic episodes where the subject is able to self-treat and that require oral carbohydrate intervention divided by the actual duration of the treatment period in days. Treatment emergent is defined as an episode that has onset in the period from initiation of treatment to end of treatment.

Time frame:
Day 1 to day 7
Reported as:
Mean · Episodes
Number of Self-manageable (Able to Self-treat) Treatment Emergent Hypoglycaemic Episodes That Require Oral Carbohydrate Intervention Per Day
Episodest50 Faster Aspart Cohort 2t65 Faster Aspart Cohort 1t40 Faster Aspart Cohort 1t65 Faster Aspart Cohort 2t30 Faster Aspart Cohort 3t65 Faster Aspart Cohort 3
Number of Self-manageable (Able to Self-treat) Treatment Emergent Hypoglycaemic Episodes That Require Oral Carbohydrate Intervention Per Day1.01 ± 0.440.87 ± 0.491.06 ± 0.570.68 ± 0.430.86 ± 0.550.51 ± 0.36
SecondaryNumber of Treatment Emergent Overall Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition

ADA classification of hypoglycaemia: 1. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. 2. Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL). 3. Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL). 4. Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a measured PG concentration \> 3.9 mmol/L (70 mg/dL) but approaching that level. 5. Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia are not accompanied by a PG determination but that was presumably caused by a PG concentration ≤ 3.9 mmol/L (70 mg/dL).

Time frame:
Day 1 to day 7
Reported as:
Number · Episodes
Number of Treatment Emergent Overall Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition
Episodest65 Faster Aspart Cohort 1t50 Faster Aspart Cohort 1t65 Faster Aspart Cohort 2t40 Faster Aspart Cohort 2t65 Faster Aspart Cohort 3t30 Faster Aspart Cohort 3
Severe hypoglycaemia000000
Documented symptomatic hypoglycaemia363824421725
Asymptomatic hypoglycaemia9158649
Probable symptomatic hypoglycaemia423315
Pseudo-hypoglycaemia383636
SecondaryNumber of Treatment Emergent Overall Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification

Overall hypoglycaemia count according to Novo Nordisk classification. Novo Nordisk classification of hypoglycaemia: 1. Severe hypoglycaemia according to the ADA classification. 2. Symptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3. Asymptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) without symptoms consistent with hypoglycaemia. 4. BG confirmed hypoglycaemia: The union of 2. and 3. 5. Severe or BG confirmed symptomatic hypoglycaemia: The union of 1. and 2. 6. Severe or BG confirmed hypoglycaemia: The union of 1., 2. and 3.

Time frame:
Day 1 to day 7
Reported as:
Number · Episodes
Number of Treatment Emergent Overall Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification
Episodest65 Faster Aspart Cohort 1t50 Faster Aspart Cohort 1t65 Faster Aspart Cohort 2t40 Faster Aspart Cohort 2t65 Faster Aspart Cohort 3t30 Faster Aspart Cohort 3
Severe hypoglycaemia000000
Symptomatic BG confirmed hypoglycaemia1312413610
Asymptomatic BG confirmed hypoglycaemia333112
BG confirmed hypoglycaemia1615714712
Severe or BG confirmed symptomatic hypoglycaemia1312413610
Severe or BG confirmed hypoglycaemia1615714712
SecondaryNumber of Treatment Emergent Daytime Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition

ADA classification of hypoglycaemia: 1. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. 2. Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL). 3. Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL). 4. Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a measured PG concentration \> 3.9 mmol/L (70 mg/dL) but approaching that level. 5. Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia are not accompanied by a PG determination but that was presumably caused by a PG concentration ≤ 3.9 mmol/L (70 mg/dL).

Time frame:
Day 1 to day 7 (in both the treatment periods)
Reported as:
Number · Episodes
Number of Treatment Emergent Daytime Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition
Episodest65 Faster Aspart Cohort 1t50 Faster Aspart Cohort 1t65 Faster Aspart Cohort 2t40 Faster Aspart Cohort 2t65 Faster Aspart Cohort 3t30 Faster Aspart Cohort 3
Severe hypoglycaemia000000
Documented symptomatic hypoglycaemia303121351422
Asymptomatic hypoglycaemia5115447
Probable symptomatic hypoglycaemia323204
Pseudo-hypoglycaemia253626
SecondaryNumber of Treatment Emergent Daytime Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification

Number of daytime hypoglycaemic episodes according to Novo Nordisk classification. Novo Nordisk classification of hypoglycaemia: 1. Severe hypoglycaemia according to the ADA classification. 2. Symptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3. Asymptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) without symptoms consistent with hypoglycaemia. 4. BG confirmed hypoglycaemia: The union of 2. and 3. 5. Severe or BG confirmed symptomatic hypoglycaemia: The union of 1. and 2. 6. Severe or BG confirmed hypoglycaemia: The union of 1., 2. and 3.

Time frame:
Day 1 to day 7
Reported as:
Number · Episodes
Number of Treatment Emergent Daytime Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification
Episodest65 Faster Aspart Cohort 1t50 Faster Aspart Cohort 1t65 Faster Aspart Cohort 2t40 Faster Aspart Cohort 2t65 Faster Aspart Cohort 3t30 Faster Aspart Cohort 3
Severe hypoglycaemia000000
Symptomatic BG confirmed hypoglycaemia1293939
Asymptomatic BG confirmed hypoglycaemia212012
BG confirmed hypoglycaemia141059411
Severe or BG confirmed symptomatic hypoglycaemia1293939
Severe or BG confirmed hypoglycaemia141059411
SecondaryNumber of Treatment Emergent Nocturnal Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition

ADA classification of hypoglycaemia: 1. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. 2. Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL). 3. Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL). 4. Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a measured PG concentration \> 3.9 mmol/L (70 mg/dL) but approaching that level. 5. Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia are not accompanied by a PG determination but that was presumably caused by a PG concentration ≤ 3.9 mmol/L (70 mg/dL).

Time frame:
Day 1 to day 7
Reported as:
Number · Episodes
Number of Treatment Emergent Nocturnal Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition
Episodest65 Faster Aspart Cohort 1t50 Faster Aspart Cohort 1t65 Faster Aspart Cohort 2t40 Faster Aspart Cohort 2t65 Faster Aspart Cohort 3t30 Faster Aspart Cohort 3
Severe hypoglycaemia000000
Documented symptomatic hypoglycaemia673733
Asymptomatic hypoglycaemia443202
Probable symptomatic hypoglycaemia100111
Pseudo-hypoglycaemia130010
SecondaryNumber of Treatment Emergent Nocturnal Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification

Number of nocturnal (from time 00:01-05:59 both inclusive) hypoglycaemic episodes according to Novo Nordisk classification. Novo Nordisk classification of hypoglycaemia: 1. Severe hypoglycaemia according to the ADA classification. 2. Symptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3. Asymptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) without symptoms consistent with hypoglycaemia. 4. BG confirmed hypoglycaemia: The union of 2. and 3. 5. Severe or BG confirmed symptomatic hypoglycaemia: The union of 1. and 2. 6. Severe or BG confirmed hypoglycaemia: The union of 1., 2. and 3.

Time frame:
Day 1 to day 7 (in both the treatment periods)
Reported as:
Number · Episodes
Number of Treatment Emergent Nocturnal Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification
Episodest65 Faster Aspart Cohort 1t50 Faster Aspart Cohort 1t65 Faster Aspart Cohort 2t40 Faster Aspart Cohort 2t65 Faster Aspart Cohort 3t30 Faster Aspart Cohort 3
Severe hypoglycaemia000000
Symptomatic BG confirmed hypoglycaemia131431
Asymptomatic BG confirmed hypoglycaemia121100
BG confirmed hypoglycaemia252531
Severe or BG confirmed symptomatic hypoglycaemia131431
Severe or BG confirmed hypoglycaemia252531
SecondaryTime in Interstitial Glucose Range Was Defined as 70-180 mg/dL (3.9-10 mmol/L) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentages)

Time in interstitial glucose range defined as 70-180 mg/dL (3.9-10 mmol/L) from initiation of treatment (day 1) to end of treatment (day 7). Time spent in interstitial glucose range is calculated as the percentage of available interstitial glucose values above or equal to the low threshold and below or equal to the high threshold.

Time frame:
Day 1 to day 7
Reported as:
Mean · Percentage
Time in Interstitial Glucose Range Was Defined as 70-180 mg/dL (3.9-10 mmol/L) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentages)
Percentaget50 Faster Aspart Cohort 1t65 Faster Aspart Cohort 1t40 Faster Aspart Cohort 2t65 Faster Aspart Cohort 2t30 Faster Aspart Cohort 3t65 Faster Aspart Cohort 3
Time in Interstitial Glucose Range Was Defined as 70-180 mg/dL (3.9-10 mmol/L) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentages)70.87 ± 9.3566.79 ± 10.3973.93 ± 6.1470.44 ± 8.4978.32 ± 6.9673.82 ± 11.79
SecondaryMean Interstitial-glucose Level

Mean interstitial glucose level is calculated as the average of the available interstitial glucose values.

Time frame:
Day 1 to day 7
Reported as:
Mean · mg/dL
Mean Interstitial-glucose Level
mg/dLt50 Faster Aspart Cohort 1t65 Faster Aspart Cohort 1t40 Faster Aspart Cohort 2t65 Faster Aspart Cohort 2t30 Faster Aspart Cohort 3t65 Faster Aspart Cohort 3
Mean Interstitial-glucose Level150.3 ± 7.8157.7 ± 11.0150.1 ± 8.5157.6 ± 11.5144.1 ± 7.1152.5 ± 11.4
SecondaryNumber of Treatment Emergent Adverse Events

Number of treatment emergent adverse events from initiation of treatment (day 1) to end of treatment (day 7). Treatment emergent is defined as an event that has onset in the period from initiation of treatment to end of treatment.

Time frame:
Day 1 to day 7
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events
Eventst50 Faster Aspart Cohort 1t65 Faster Aspart Cohort 1t40 Faster Aspart Cohort 2t65 Faster Aspart Cohort 2t30 Faster Aspart Cohort 3t65 Faster Aspart Cohort 3
Number of Treatment Emergent Adverse Events222001
SecondaryNumber of Treatment Emergent Infusion Site Reactions

Number of treatment-emergent infusion site reactions from initiation of treatment (day 1) to end of treatment (day 7). Treatment emergent is defined as an event that has onset in the period from initiation of treatment to end of treatment.

Time frame:
Day 1 to day 7
Reported as:
Number · Infusion site reaction
Number of Treatment Emergent Infusion Site Reactions
Infusion site reactiont50 Faster Aspart Cohort 1t65 Faster Aspart Cohort 1t40 Faster Aspart Cohort 2t65 Faster Aspart Cohort 2t30 Faster Aspart Cohort 3t65 Faster Aspart Cohort 3
Number of Treatment Emergent Infusion Site Reactions000001
SecondaryTotal Insulin Dose Per Day

Total insulin dose (U/kg) per day from initiation of treatment (day 1) to end of treatment (day 7). Total daily insulin dose is calculated as the sum of all insulin doses delivered by the iLet™ divided by the actual duration of the treatment period in days.

Time frame:
Day 1 to day 7
Reported as:
Mean · U/Kg/day
Total Insulin Dose Per Day
U/Kg/dayt50 Faster Aspart Cohort 1t65 Faster Aspart Cohort 1t40 Faster Aspart Cohort 1t65 Faster Aspart Cohort 2t30 Faster Aspart Cohort 3t65 Faster Aspart Cohort 3
Total Insulin Dose Per Day0.60 ± 0.120.63 ± 0.120.65 ± 0.130.67 ± 0.160.63 ± 0.120.64 ± 0.18

Adverse events

Collected over From the first trial-related activity (screening, day -14) after obtaining informed consent and until the follow up visit (treatment days 7 in both periiods+7 days follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
t50 Faster Aspart Cohort 10/8 (0%)0/8 (0%)2/8 (25%)
t65 Faster Aspart Cohort 10/8 (0%)0/8 (0%)1/8 (12.5%)
t40 Faster Aspart Cohort 20/8 (0%)0/8 (0%)1/8 (12.5%)
t65 Faster Aspart Cohort 20/8 (0%)0/8 (0%)0/8 (0%)
t30 Faster Aspart Cohort 30/8 (0%)0/8 (0%)0/8 (0%)
t65 Faster Aspart Cohort 30/7 (0%)0/7 (0%)1/7 (14.3%)
Most frequent other events
Most frequent other events
Eventt50 Faster Aspart Cohort 1t65 Faster Aspart Cohort 1t40 Faster Aspart Cohort 2t65 Faster Aspart Cohort 2t30 Faster Aspart Cohort 3t65 Faster Aspart Cohort 3
Infusion site reactionGeneral disorders0/80/80/80/80/81/7
HyperglycaemiaMetabolism and nutrition disorders1/81/80/80/80/80/7
PyrexiaGeneral disorders0/80/81/80/80/80/7
Viral upper respiratory tract infectionInfections and infestations1/80/80/80/80/80/7
VomitingGastrointestinal disorders0/80/81/80/80/80/7

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1Cohort 2Cohort 3Total
Mean45.5 ± 13.536.3 ± 14.847.1 ± 10.743.0 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Total
Female67518
Male2136
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White78823
More than one race0000
Unknown or Not Reported1001
08

Study locations

1 site
  • Novo Nordisk Investigational Site
    Boston, Massachusetts 02114, United States
09

References and documents

Publications

  • Russell SJ, Balliro C, Ekelund M, El-Khatib F, Graungaard T, Greaux E, Hillard M, Jafri RZ, Rathor N, Selagamsetty R, Sherwood J, Damiano ER. Improvements in Glycemic Control Achieved by Altering the tmax Setting in the iLet(R) Bionic Pancreas When Using Fast-Acting Insulin Aspart: A Randomized Trial. Diabetes Ther. 2021 Jul;12(7):2019-2033. doi: 10.1007/s13300-021-01087-x. Epub 2021 Jun 19. PubMed 34146238 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in May 2019, 3 months.

Results were first posted in Jun 2020, 1 year after primary completion.

Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 3 months is below that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2019
First posted
Jan 25, 2019
StartActual
Feb 25, 2019
Primary completionActual
May 31, 2019
CompletionActual
Jun 10, 2019
Results first posted
Jun 11, 2020
Last update
Jun 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03816761
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 25, 2019
Start date
Feb 25, 2019
Primary completion
May 31, 2019
Completion
Jun 10, 2019
Results posted
Jun 11, 2020
Last update
Jun 11, 2020

Study contacts

Clinical Reporting Anchor and Disclosure (1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Aspart

Start the discussion